deucravacitinib
bms
['lupus', 'genesis', 'deucra']
plenary:
tyrosine kinase 2 (tyk2) mediates signaling of type i ifns, il-23, and il-12 key cytokines involved in lupus pathogenesis deucravacitinib oral tyk2 inhibitor phase 2 rct in sle showed efficacy
pike m abs1117 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach